US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
カナダ
CSE
ChitogenX Inc (CHGX) 銘柄情報

ChitogenX Inc (CHGX)

0.005

0.00

(0.00%)

終了 6月23日 5:00AM

ChitogenX Inc (CHGX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.005

( - )

買値

0.005

売値

0.005

出来高

-

0.00 日の範囲 0.00

0.005 52 週間の範囲 0.005

時価総額

前日終値

0.005

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

$ 0

発行済株式数

83,129,520

配当利回り

PER

-0.28

1 株当たり利益 (EPS)

-0.02

歳入

-

純利益

-1.55M

ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff re... ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.chitogenx.com

本社

Kirkland, Canada

設立

2026

ChitogenX Inc is listed in the Healthcare sector of the Canadian Securities Exchange with ticker CHGX. The last closing price for ChitogenX was $0.01. Over the last year, ChitogenX shares have traded in a share price range of $ 0.005 to $ 0.005.

ChitogenX currently has 83,129,520 shares in issue. The market capitalisation of ChitogenX is $415,647.60 . ChitogenX has a price to earnings ratio (PE ratio) of -0.28.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.005	0.005	0.005	0	0	CS
4	0	0	0.005	0.005	0.005	0	0	CS
12	0	0	0.005	0.005	0.005	0	0	CS
26	0	0	0.005	0.005	0.005	0	0	CS
52	0	0	0.005	0.005	0.005	0	0	CS
156	-0.125	-96.1538461538	0.13	0.14	0.005	28357	0.02527226	CS
260	-0.245	-98	0.25	0.31	0.005	27787	0.05791494	CS

CHGX - Frequently Asked Questions (FAQ)

What is the current ChitogenX Inc share price?

The current share price of ChitogenX Inc is $ 0.005

How many ChitogenX Inc shares are in issue?

ChitogenX Inc has 83,129,520 shares in issue

What is the market cap of ChitogenX Inc?

The market capitalisation of ChitogenX Inc is CAD 415.65k

What is the 1 year trading range for ChitogenX Inc share price?

ChitogenX Inc has traded in the range of $ 0.005 to $ 0.005 during the past year

What is the PE ratio of ChitogenX Inc?

The price to earnings ratio of ChitogenX Inc is -0.28

What is the registered address of ChitogenX Inc?

The registered address for ChitogenX Inc is 16667 Hymus Boulevard, Kirkland, Quebec, H9H 4R9

What is the ChitogenX Inc website address?

The website address for ChitogenX Inc is www.chitogenx.com

Which industry sector does ChitogenX Inc operate in?

ChitogenX Inc operates in the Biotechnology & Life Sciences sector

Methinks

Methinks 5分前

I am keeping an eye on Infineon stocks. Up by 200% in the last few months. They are developing the TPM in Europe.

boston127

boston127 6分前

Thanks for this. I will buy

get into this one after 10 AM. The other one is flying again, beginning right at 4 AM.

100lbStriper

100lbStriper 7分前

franks summary.........„The Director further explains exceptional circumstances warranting an additional extension may include: dismissal of all or substantially all claims in a co-pending litigation, findings of fact and conclusions of law that render all or substantially all challenged claims inva

boston127

boston127 10分前

It is 4 AM, and we are flying

Price is .026, up 34%, and volume is 76M.

100lbStriper

100lbStriper 11分前

SilviaJ $NLST Trend Force expects the memory market's revenue to reach $889.3 billion in 2026, while the 2027 forecast stands at a whopping $1.28 trillion.

Counterpoint Research: The DRAM market's revenue is anticipated to increase by 4x in 2026 to $618.7 billion, followed by a 46%

gitreal

gitreal 13分前

Don't go away mad. Either respond to the charges, or block them so you don't have to see them. Fleeing from the board completely only makes it seem that the charges are true. Are they?

We need those reports on your first-person visits to the Bishop plant, they've been very inform

100lbStriper

100lbStriper 15分前

UNITED STATES PATENT AND TRADEMARK OFFICE https://www.uspto.gov/sites/default/files/documents/ipr2025-01072-dr-paper_30.pdf

100lbStriper

100lbStriper 19分前

and to think i could of dumped those roof shares at better than 350!!! free roof, profit, and principal back with taxs paid, but noooooo..........i want more!!!!!!!

mm41

S&P 500 vs. S&P 493: Where smart money is buying in silence right now
Read the Full article here https://www.linkedin.com/pulse/sp-500-illusion-you-reading-headlines-did-actually-do-mirjana-garison-6cz0e/

ducci1

ducci1 42分前

Charts: SPY Support--- 23% Retrace Fib at 730.31 !

ducci1

ducci1 47分前

Charts: Falling Channels Confirmed-----ES Lower Trendline 7395----SPY Lower T/L 733.45 !

nowwhat2

nowwhat2 53分前

Remarkable reporting (if I do say so myself) he-he

https://investorshub.advfn.com/uimage/uploads/2026/6/23/ysrgibtc_june_22_1m_1045pm_SUMMARY_66666_FOMC_GUTSY.jpg

:45 minutes later and.....
https://investorshub.advfn.com/uimage/uploads/2026/6/23/guikmbtc_june_2

US Market News

US Market News 1時間前

LiveRamp Partners with Adobe to Bring Commerce Purchase Data into GenStudio for Commerce Media NetworksJune 23, 2026 3:00 AM
Business WireAdobe GenStudio for Commerce Media Networks addresses key creative, data, and activation needsLiveRamp (NYSE: RAMP),

US Market News

US Market News 1時間前

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque PsoriasisJune 23, 2026 3:00 AM
PR Newswire (US) SKYRIZI® (risankizumab) expands i

US Market News

US Market News 1時間前

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque PsoriasisJune 23, 2026 3:00 AM
PR Newswire (US) SKYRIZI® (risankizumab) expands i

US Market News

US Market News 1時間前

Clarivate Releases 2025 Sustainability ReportJune 23, 2026 3:00 AM
PR Newswire (US) New report highlights progress against goals and a decline in total carbon emissions class="legendSpanClass"LONDON, class="legendSpanClass"June 23, 2026

nowwhat2

nowwhat2 1時間前

Remarkable reporting (if I do say so myself) he-he

https://investorshub.advfn.com/uimage/uploads/2026/6/23/ysrgibtc_june_22_1m_1045pm_SUMMARY_66666_FOMC_GUTSY.jpg

:45 minutes later and.....
https://investorshub.advfn.com/uimage/uploads/2026/6/23/guikmbtc_june_2

WooptdooU

WooptdooU 1時間前

Seeking Alpha article is INCREDIBLY POSITIVE, just read it!!!
It is written Nearly ALL POSITIVE facts and negative opinion, just a real whimper level of faith, trust and risk tolerance. It is also Just incredible to read the nearly bear case scenario of present value pricing lists a HIGHER pr

US Market News

US Market News 1時間前

Tradeweb Launches Spread Trading for European Credit PortfoliosJune 23, 2026 3:00 AM
Business Wire Enables portfolio-level execution on a spread within a single, integrated workflow Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic tradi

shajandr

shajandr 1時間前

As usual, you're a funny guy.

Like a clown.

https://www.youtube.com/watch?v=Pfcy15ZUE2c

Tom turtles

Tom turtles 1時間前

What a monster.....Holding 50k from .,28

Ray_137

Ray_137 1時間前

So now Jack fruit in July.

FORDGT

FORDGT 2時間前

Significant Failures to Deliver
Yes

0.5% until 9feb2029

AusNet Services

Resmed Inc Dl 004

Cobram Estate Olives

JPM USD High Yield Bond ...

Societe Generale Effekten

Nts Lkd Uksed3p Srs 2749...

MFEMediaForEurope

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。